From PCOS to PMOS: understanding the reasons for name change, Pg2

Key Highlights:

• The Endocrine Society has renamed Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
• The name change aims to reflect the diverse endocrine and metabolic factors beyond ovarian cysts.
• PCOS affects an estimated 170 million women globally during their reproductive years.
• The new nomenclature is expected to improve diagnosis and treatment of the syndrome.

Detailed Insights:

• The term PCOS was considered inaccurate as it focused solely on ovarian cysts, overlooking other contributing factors.
• The new name, PMOS, broadens the scope to include diverse endocrine and metabolic features, facilitating better diagnosis.
• Experts believe the change will reduce misdiagnosis, overdiagnosis, and self-diagnosis associated with PCOS.
• Paediatric endocrinologists already follow a comprehensive approach, considering polyendocrine factors beyond ovarian issues.
• Implementation of the new name involves an eight-stage process, aiming for integration into international guidelines by 2028.
• Awareness campaigns are crucial to ensure the community understands the broader implications of PMOS.
• Some experts believe the success of the name change depends on professional societies and the awareness among gynaecologists regarding the metabolic aspects of the syndrome.

Key Concepts Involved:

• Endocrine System: The collection of glands that produce hormones regulating various bodily functions.
• Metabolic Syndrome: A cluster of conditions that increase the risk of heart disease, stroke, and diabetes.
• Ovarian Cysts: Fluid-filled sacs that can develop on the ovaries.